A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children

详细信息    查看全文

• 作者：Wei Zhu ; Br ; on W. Higgs ; Chris Morehouse ; Katie Streicher ; Christopher S. Ambrose ; Jennifer Woo ; George W. Kemble ; Bahija Jallal ; Yihong Yao
• 关键词：Influenza vaccine ; Oligonucleotide microarray ; Pediatric
• 刊名：Vaccine
• 出版年：2010
• 出版时间：1 April 2010
• 年：2010
• 卷：28
• 期：16
• 页码：2865-2876
• 全文大小：1566 K

文摘

The protective mechanisms of influenza vaccines in young children are not completely understood. A phase 2 clinical study was conducted in 85 children 12–35 months of age to describe and compare the immune responses to live attenuated influenza vaccine (LAIV) with trivalent inactivated influenza vaccine (TIV). To better understand the biology of vaccine effects, oligonucleotide microarrays were employed to measure the genome-wide changes in transcript profiles in whole blood at approximately 7 days after 1 dose of LAIV or TIV. Of the total 265 differentially expressed genes identified in this study, 6 clusters of genes were identified to be tightly coexpressed, many of which are likely modulated by cytokines including type 1 interferons (IFNs) and granulocyte–macrophage colony-stimulating factor. Additional functional analyses revealed that the type 1 IFN pathway and cell cycle regulation-related genes are enriched in the 6 coexpressed gene sets. Promoter characterization of these coexpressed genes also supported this conclusion. Moreover, it is suggested that the IFN-stimulated response element is likely to be a potential bidirectional promoter, and the CCAAT/enhancer-binding protein might cooperate with the E2F transcription factor family in the regulation of the cell cycle in the early immune response induced by the influenza vaccine. Overall, our study clearly indicates that the expression profile changes induced by LAIV are significantly different from those induced by TIV. These results suggest that the pattern of overexpression of type 1 IFN-stimulated genes can potentially be used as a biomarker to identify the early vaccination response of LAIV and may also explain, to a certain extent, previous clinical study observations of LAIV-induced protection against influenza-like illness in the first 2 weeks after administration.